

## PREVENTION & THERAPIES FOR HEPATITIS AND CHRONIC LIVER DISEASE

**Houston, TX April 2, 2022**

Conference Location	<b>DoubleTree Houston at Greenway Plaza</b> 6 Greenway Plaza, E. Houston, TX	<b>Phone: (713) 629-1200</b>  <a href="https://www.hilton.com/en/hotels/hougwdt-doubletree-houston-greenway-plaza/">https://www.hilton.com/en/hotels/hougwdt-doubletree-houston-greenway-plaza/</a>
------------------------	---	---

Parking at the Seminar	A reduced daily parking rate of \$10 has been arranged for you. Please bring the parking ticket to the seminar registration desk to receive this rate
------------------------	---

Driving Directions	<b>From the Downtown Houston</b> <ul style="list-style-type: none"> <li>Get on I-69 from La Branch Stree</li> <li>Follow I-69 to SW Freeway Service Road/Southwest Freeway</li> <li>Take Exit 125 A. Follow signs for Wesleyan Road</li> <li>Take the Edloe Ramp and bear Right onto Edloe Driveway and East Greenway Plaza</li> <li>The road will bend Left and then the hotel will be on the right</li> </ul>
-----------------------	---

Seminar Agenda and Syllabus Information	Registration begins at <b>7:00am</b> in the <b>Plaza Ballroom – 20<sup>th</sup> floor</b> . Please check signage for any last-minute room changes.  <b>The Emerging Therapies seminar is a paperless program.</b> The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the <i>App</i> will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.
---	--

<b>Pre-Program Activities</b>	<b>Lecture 1 – Viral Hepatitis</b> –A summary for discovery and natural history of HCV 60 min <b>Lecture 2 - End Stage Liver Disease:</b> An overview of Treatment, Managing Complications chronic liver disease, cirrhosis, and the transplant process – 45 min
<b>7:00am</b>	<b>Registration and View Exhibits</b>
<b>7:30 am</b>	<b>Opening Comments and Pre-Test</b>
<b>7:45 am</b>	<b>Hepatitis C: Update on Diagnostics</b> <ul style="list-style-type: none"> <li>Short recap of key points from Pre-course lecture on viral hepatitis</li> <li>Screening and diagnostic approaches of HCV</li> </ul> <b>Hepatitis C: Update on Treatment</b> <ul style="list-style-type: none"> <li>AASLD/IDSA Guidelines and Updates</li> <li>Simplified Guidance</li> </ul> <b>Case Studies 1 and 2</b> –New Case relevant to diagnosis and treatment of high-risk HCV patient
<b>8:35am</b>	<b>Hepatitis B: Epidemiology, Natural History and Testing</b> <ul style="list-style-type: none"> <li>The epidemiology of the Hepatitis B infection</li> <li>Efficacies and opportunities in HBV testing and vaccination</li> </ul> The growing relationship between HBV and HDV
<b>9:05 am</b>	<b>Anti-viral Therapies for HBV</b> <ul style="list-style-type: none"> <li>Early detection and treatment approaches</li> <li>Treating HCC in patients with Hepatitis B</li> </ul> Reactivation of HBV
<b>9:35 am</b>	<b>Industry Presentation #1 Break and View exhibits</b>

<b>10:15 am</b>	<b>Delta Hepatitis and Hepatitis E Update</b> <ul style="list-style-type: none"> <li>Worldwide perspective and promising research studies</li> <li>Real world outcome studies on HDV and HEV</li> </ul>
<b>10:45 am</b>	<b>End Stage Liver Disease: Recap and Clinical Case</b> <ul style="list-style-type: none"> <li>A review of Pre-course lecture touching on staging, work-up and remedies for cirrhosis and the liver transplant process</li> </ul>
<b>11:15 am</b>	<b>Alcoholic Liver Disease</b> <ul style="list-style-type: none"> <li>The growing prevalence of alcohol over-consumption and its impact on liver health</li> </ul> Warning signs and intervention in alcoholic hepatitis
<b>11:45 am</b>	<b>Hepatocellular Carcinoma (HCC)</b> <ul style="list-style-type: none"> <li>Screening diagnostic serum assays and imaging tests</li> </ul> Treatment and management options: Ablation, TACE and Surgery
<b>12:15 pm</b>	<b><i>Luncheon and Industry Presentation #2</i></b>
<b>1:00pm</b>	<b><i>Dessert and View Exhibits</i></b>
<b>1:10 pm</b>	<b>Hepatocellular Carcinoma: New Systemic Treatment Options</b> <ul style="list-style-type: none"> <li>Current FDA-Approved Therapies</li> <li>New chemotherapy regimens in development and testing</li> <li>Immunotherapy as the new MoA for HCC</li> </ul> <b>Case Study 3–</b> Diagnosis and Treatment of Hepatocellular Carcinoma
<b>1:40 pm</b>	<b>SARS-COV-2 in Liver Disease</b> <ul style="list-style-type: none"> <li>Effect of COVID on the liver and in cirrhotic patients</li> </ul> COVID-19 challenges for liver transplant recipients
<b>2:10pm</b>	<b>Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis</b> <ul style="list-style-type: none"> <li>Epidemiology of PSC and Ursodiol and Antibiotic Treatments</li> <li>Predicting outcomes and Improving Survival in PSC patients</li> <li>Causes and Markers of PBC</li> </ul> Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
<b>2:45 pm</b>	<b><i>Break &amp; View Exhibits</i></b>
<b>3:00 pm</b>	<b>NAFLD and NASH</b> <ul style="list-style-type: none"> <li>Epidemiology, Demographics and Diagnosis</li> <li>Scoring, Staging and Management of Fatty Liver Disease</li> </ul> Treatment options for thrombocytopenia; including alternatives to platelet transfusion.
<b>3:35 pm</b>	<b>NASH Treatments in Practice and in Development</b> <ul style="list-style-type: none"> <li>Current therapies for NASH including Updates from AASLD and EASL</li> <li>Lifestyle changes as a therapy</li> </ul> Drugs in clinical development for NASH
<b>4:25 pm</b>	<b>Closing Comments, Post-test and Wrap-Up</b> Program adjourns at 4:45 pm
<b>Post-program activities</b>	<b>Lecture 3 - Viral Hepatitis Updates: The reemergence of Hepatitis A and Overcoming barriers to liver health in special populations - 60 minutes</b>

---

**Attendance  
Policies**

**Attendee Cancellation, Substitution, Refund**

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

**Recording and Photography**

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

**Guest Attendance**

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

**Conference Modification or Cancellation**

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

---

**CME  
Information**


**Physicians (MD/DO)** - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **10.0 AMA PRA Category 1 Credit(s)™**.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses** - This program has been approved by the Kentucky Board of Nursing for 12.0 continuing education credits through University of Louisville Hospital, provider number 4-0068-12-22-1264. The Kentucky Board of Nursing approval of an individual nursing education provider does not constitute endorsement of program content.

**Nurse Practitioners and Physician Assistants** - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)™ organizations accredited by ACCME.

**Your  
Seminar  
Faculty**



**VICTOR MACHICAO, MD**

Victor Machicao received his medical degree from the Universidad Peruana Cayetano Heredia in Lima, Peru. He completed his residency in Internal Medicine at the Cleveland Clinic Foundation, and his Gastroenterology and Hepatology Fellowship training at the Mayo Clinic in Jacksonville, Florida. In addition, he also completed a Fellowship in Hepatology and Liver Transplantation at the Mayo Clinic.

Dr Machicao is currently an Associate Professor of Medicine at the McGovern Medical School at University of Texas Health Science Center at Houston and is Director of the Texas Liver Center at the Ertan Digestive Disease Center, and Medical Director of the Liver Transplant Program at Memorial Hermann Hospital at the Texas Medical Center.



**SAIRA KHADERI, MD, MPH**

Saira A. Khaderi, M.D is Assistant Professor of Surgery in the Division of Abdominal Transplantation of the Michael E. DeBakey Department of Surgery at Baylor College of Medicine. She is also the assistant director of ECHO Texas, a program that partners Baylor faculty with medical providers in rural and underserved communities. ECHO programs aim to improve medical expertise and health outcomes using video conferencing to develop expert health care networks to manage complex diseases. Dr. Khaderi is board certified in internal medicine.

Dr. Khaderi earned her medical degree from The University of Texas Medical Branch in Galveston, Texas and her Masters in Public Health from The University of Texas School of Public Health in Houston, Texas. She joined the Division of Abdominal Transplantation in 2013. Dr. Khaderi's clinical interests include transplant, hepatitis C, cirrhosis and end-stage liver disease (ESLD).



**LINE K. HINOJOSA, FNP, MSN**

Line K. Hinojosa, FNP is a faculty member with the Division of Abdominal Transplantation/Surgery at Baylor St. Luke's Medical Center. She serves as the lead advanced practice provider for the department of Hepatology. Line is a board-certified Family Nurse Practitioner.

Line earned her Bachelor of Science in Nursing degree at Texas Tech University in 2010. From there, she spent 2 years in medical surgical nursing, followed by 6 years in the surgical and liver transplant intensive care unit. She completed her Masters of Science in Nursing Degree from Texas Woman's University in 2017. She joined the division of abdominal transplantation and hepatology in 2018. Line's clinic interests include Cirrhosis, Hepatitis B, and Hepatitis C.